385 related articles for article (PubMed ID: 9364999)
1. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
Elg M; Gustafsson D; Deinum J
Thromb Haemost; 1997 Oct; 78(4):1286-92. PubMed ID: 9364999
[TBL] [Abstract][Full Text] [Related]
2. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD
Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603
[TBL] [Abstract][Full Text] [Related]
3. Thrombin inhibitors and anti-coagulants on thrombin-induced embolisation in rabbit cranial vasculature.
Liu JT; Paul W; Emerson M; Cicala C; Page CP
Eur J Pharmacol; 1994 Oct; 264(2):183-90. PubMed ID: 7851481
[TBL] [Abstract][Full Text] [Related]
4. [Direct thrombin antagonists].
Lankes W; Fleischer K; Gulba DC
Herz; 2001 Apr; 26 Suppl 1():46-52. PubMed ID: 11349627
[TBL] [Abstract][Full Text] [Related]
5. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
[TBL] [Abstract][Full Text] [Related]
6. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes.
Gustafsson D; Antonsson T; Bylund R; Eriksson U; Gyzander E; Nilsson I; Elg M; Mattsson C; Deinum J; Pehrsson S; Karlsson O; Nilsson A; Sörensen H
Thromb Haemost; 1998 Jan; 79(1):110-8. PubMed ID: 9459334
[TBL] [Abstract][Full Text] [Related]
7. Modulating platelet function with selective thrombin inhibitors.
Verstraete M
Haemostasis; 1996 Oct; 26 Suppl 4():70-7. PubMed ID: 8979113
[TBL] [Abstract][Full Text] [Related]
8. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro.
Nielsen VG; Steenwyk BL; Gurley WQ; Pereira SJ; Lell WA; Kirklin JK
J Heart Lung Transplant; 2006 Jun; 25(6):653-63. PubMed ID: 16730571
[TBL] [Abstract][Full Text] [Related]
9. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
[TBL] [Abstract][Full Text] [Related]
10. Effective use of BCH-2763, a new potent injectable direct thrombin inhibitor, in combination with tissue plasminogen activator (tPA) in a rat arterial thrombolysis model.
Deschênes I; Finkle CD; Winocour PD
Thromb Haemost; 1998 Jul; 80(1):186-91. PubMed ID: 9684808
[TBL] [Abstract][Full Text] [Related]
11. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
Freund M; Mantz F; Nicolini P; Gachet C; Mulvihill J; Meyer L; Beretz A; Cazenave JP
Thromb Haemost; 1993 May; 69(5):515-21. PubMed ID: 8322274
[TBL] [Abstract][Full Text] [Related]
12. The influence of direct and antithrombin-dependent thrombin inhibitors on the procoagulant and anticoagulant effects of thrombin.
Linder R; Frebelius S; Grip L; Swedenborg J
Thromb Res; 2003 Jun; 110(4):221-6. PubMed ID: 14512086
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of thrombin generation in plasma by inhibitors of factor Xa.
Prasa D; Svendsen L; Stürzebecher J
Thromb Haemost; 1997 Oct; 78(4):1215-20. PubMed ID: 9364987
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban.
Komatsu Y; Inoue Y; Goto Y; Fukazawa T; Hayashi H
Thromb Haemost; 1999 Feb; 81(2):250-5. PubMed ID: 10064001
[TBL] [Abstract][Full Text] [Related]
15. Thrombin, an ideal target for pharmacological inhibition: a review of direct thrombin inhibitors.
Gurm HS; Bhatt DL
Am Heart J; 2005 Jan; 149(1 Suppl):S43-53. PubMed ID: 15644793
[No Abstract] [Full Text] [Related]
16. Predicting the pharmacology of thrombin inhibitors.
Adams TE; Everse SJ; Mann KG
J Thromb Haemost; 2003 May; 1(5):1024-7. PubMed ID: 12871372
[TBL] [Abstract][Full Text] [Related]
17. Direct thrombin inhibitors are not equally effective in vivo against arterial thrombosis: in vivo evaluation of DuP714 and argatroban in a porcine angioplasty model and comparison to r-hirudin.
McBane RD; Hassinger NL; Mruk JS; Grill DE; Chesebro JH
Thromb Res; 2005; 116(6):525-32. PubMed ID: 16181988
[TBL] [Abstract][Full Text] [Related]
18. Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin.
Meyer BJ; Badimon JJ; Chesebro JH; Fallon JT; Fuster V; Badimon L
Circulation; 1998 Feb; 97(7):681-5. PubMed ID: 9495304
[TBL] [Abstract][Full Text] [Related]
19. Direct thrombin inhibitors in cardiac disease.
Weitz JI; Bates ER
Cardiovasc Toxicol; 2003; 3(1):13-25. PubMed ID: 12668887
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulation: the present and future.
Van Aken H; Bode C; Darius H; Diehm C; Encke A; Gulba DC; Haas S; Hacke W; Puhl W; Quante M; Riess H; Scharf R; Schellong S; Schrör T; Schulte KL; Tebbe U
Clin Appl Thromb Hemost; 2001 Jul; 7(3):195-204. PubMed ID: 11441979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
